FOI 7273 - Information with regards to Melanoma treatment

Date: 26 April 2022 to 26 April 2025

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

 

  • Bevacizumab (Avastin)

 

  • Dacarbazine (DTIC)

 

  • Trametinib (Mekinist)

 

  • Dabrafenib (Tafinlar)

 

  • Ipilimumab (Yervoy)

 

  • Vemurafenib (Zelboraf)

 

  • Nivolumab (Opdivo)

 

  • Nivolumab + Ipilimumab (Opdivo + Yervoy)

 

  • Pembrolizumab (Keytruda)

 

  • Vemurafenib + cobimetinib (Zelboraf + Cotellic)

 

  • Dabrafenib + Trametinib (Tafinlar + Mekinist)

 

  • Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients

 

  • Other active systemic anti-cancer therapy [please state]

 

  • Palliative care only

 

 

 

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

 

  • Ipilimumab

 

  • Ipilimumab AND Nivolumab

 

  • Nivolumab

 

  • Pembrolizumab

 

  • Dabrafenib AND Trametinib

 

  • Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib  /Trametinib  /Vemurafenib  /Vemurafenib AND Cobimetinib)

 

  • Other active systemic anti-cancer therapy

 

  • Palliative care only
  • Request ID:
    7273
  • Category:
    Clinical - Drugs
  • Response:

    April 2022

    Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

    • Bevacizumab (Avastin)
    • Dacarbazine (DTIC)
    • Trametinib (Mekinist)
    • Dabrafenib (Tafinlar)
    • Ipilimumab (Yervoy)
    • Vemurafenib (Zelboraf)
    • Nivolumab (Opdivo)
    • Nivolumab + Ipilimumab (Opdivo + Yervoy)
    • Pembrolizumab (Keytruda)
    • Vemurafenib + cobimetinib (Zelboraf + Cotellic)
    • Dabrafenib + Trametinib (Tafinlar + Mekinist)
    • Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
    • Other active systemic anti-cancer therapy [please state]
    • Palliative care only

    *Please see below.

     

    Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

    • Ipilimumab
    • Ipilimumab AND Nivolumab
    • Nivolumab
    • Pembrolizumab
    • Dabrafenib AND Trametinib
    • Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib  /Trametinib  /Vemurafenib  /Vemurafenib AND Cobimetinib)
    • Other active systemic anti-cancer therapy
    • Palliative care only

     

    *Medway NHS Foundation regret this data is not collated.  The Trust’s Pharmacy department can confirm the number of patients that have been issued the drug, but pharmacy do not hold details of the indication that each drug was prescribed for.  Therefore please see below data held for the reporting period 01/01/2022 to 31/03/2022 for all indications, not just melanoma patients.  If the drug is not listed, it is because it has not been issued.

     

    Drug

    Total Number of Patients

    DACARBAZINE

    <5

    IPILIMUMAB (YERVOY)

    <5

    NIVOLUMAB (OPDIVO)

    10

    PEMBROLIZUMAB

    39